



Article scientifique

Article

2021

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

Sterile peri-graft abscess formation following aortic replacement: A word of caution for usage of BioGlue®

Yilmaz, Nurten; Sologashvili, Tornike; Huber, Christoph; Cikirikcioglu, Mustafa

How to cite

YILMAZ, Nurten et al. Sterile peri-graft abscess formation following aortic replacement: A word of caution for usage of BioGlue®. In: The International Journal of Artificial Organs, 2021, vol. 44, n° 11, p. 917–919. doi: 10.1177/03913988211045091

This publication URL: <https://archive-ouverte.unige.ch/unige:157713>

Publication DOI: [10.1177/03913988211045091](https://doi.org/10.1177/03913988211045091)

Sterile peri-graft abscess formation following aortic replacement: A word of caution for usage of BioGlue®

Nurcan Yilmaz^{id}, Tornike Sologashvili, Christoph Huber^{id}
and Mustafa Cikirikcioglu

The International Journal of Artificial
Organs

2021, Vol. 44(11) 917–919

© The Author(s) 2021



Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/03913988211045091

journals.sagepub.com/home/jao



Abstract

We report sterile peri-graft abscess formation following an ascending aortic and hemiarch replacement for acute type A aortic dissection, possibly caused as a reaction to BioGlue®. The patient was successfully treated by drainage, cleaning, removal of BioGlue® remnants, three sessions of negative-pressure wound dressing, and secondary chest closure.

Keywords

BioGlue, sterile abscess, tissue sealant, ascending aortic replacement, cardiac surgery

Date received: 4 May 2021; accepted: 18 August 2021

Introduction

Many different tissue sealants are available on the market today. Indications for using these products include supporting suture lines to achieve better hemostasis, strengthening of the fragile tissues, and inducing adherence between tissues for faster healing.¹ BioGlue® (CryoLife International Inc, Kennesaw, GA) is one of the most widely used surgical adhesive agent. It is composed of purified bovine serum albumin and glutaraldehyde, which, combined, form a covalent bond between their molecules and the tissue proteins at the surgical site, resulting in a mechanical seal.² We report a sterile peri-graft abscess formation following an ascending aortic and hemiarch replacement for acute type A aortic dissection, possibly caused as a reaction to BioGlue®.

Clinical summary

A 54-year-old male patient underwent an emergency ascending and hemi-arch aortic replacement for acute type A dissection (Figure 1(a)). The anastomotic suture line was reinforced by application of BioGlue® tissue sealant due to the difficulty in achieving satisfactory hemostasis, which is not routinely used in our local protocol. The initial post-operative course was uneventful. On postoperative day (POD) 7, the patient developed fever and an

inflammatory syndrome. Blood culture was negative. A broad-spectrum antibiotic therapy was started due to a suspicion of pneumonia. Chest CT scan was performed on POD 11 because of a persistent fever and an inflammatory syndrome showed a suspicious peri-graft fluid collection (Figure 1(b)). The patient underwent a surgical revision for a suspicion of acute mediastinitis. During the procedure, a whitish milky liquid was drained (Figure 1(c)). The surgical site was drained, mechanically cleaned with water jet (OrthoLav®) to remove all remnants of BioGlue®. The chest was left open with a negative-pressure wound dressing. The patient became rapidly afebrile and the inflammatory markers normalized. The histopathologic analysis of the peri-graft process didn't seem related to an infectious abscess. Indeed, a fibrin-inflammatory reaction without microorganisms in direct microscopic observation and dedicated staining was found. After a 10 days follow-up with three consecutive vacuum dressing changes, the chest was closed and patient's recovery was uneventful without

Division of Cardiovascular Surgery, Department of Surgery, University Hospitals and Faculty of Medicine, Geneva, Switzerland

Corresponding author:

Mustafa Cikirikcioglu, Division of Cardiovascular Surgery, University Hospital of Geneva, Rue Gabrielle Perret-Gentil 4, Geneva 1211, Switzerland.

Email: mustafa.cikirikcioglu@hcuge.ch




Figure 1. (a) Contrast-enhanced chest computed tomography: acute type A dissection with true lumen (TL) and false lumen (FL), (b) contrast-enhanced chest computed tomography: peri-graft fluid collection (arrow), (c) operative view. Peri-graft (asterix) fluid collection (arrow), and (d) contrast-enhanced chest computed tomography: no residual collection.

fever or any inflammatory response. He was discharged to another hospital at POD seven following final sternal closure. All samples which were analyzed by broad spectrum microbiological cultures remained negative throughout. Three months after surgery, a chest CT control showed regular post-operative images without having any residual collection (Figure 1(d)).

Discussion

Several studies reported complications potentially attributed to use of BioGlue® like toxicity to nerves and cardiac conduction tissue, re-dissection, pseudo-aneurysm formation, and adhesive embolization. Valve dysfunction due to deposits of the glue on prosthetic valve leaflets after leakage through aortic suture lines was also reported. Some reports have described tissue damages (necrotic, fibrosed, and excessively thinned aortic tissue) which were observed during reoperations at the site of BioGlue® application.² The formation of a sterile abscess following this product is a very rare complication as evidenced by some case reports in the literature.^{2,3} Although the mechanism of the sterile abscess formation is not clearly associated to BioGlue®, the localized collection of the liquid next to this product remnants reminds us of the need to use this product with caution. The mechanism behind this complication could be secondary to a massive foreign-body reaction with, at histological examination, numerous multinucleated giant cells.^{4,5} Surgical drainage, mechanical cleaning, removal of the tissue sealant remnants can be applied as

an effective treatment on the spot of sterile abscess collection.³ However, in our experience, a suspicion of mediastinitis because of the presence of an infective-like liquid collection, leaving the wound open with a negative pressure dressing until a sterile abscess is proven seems to be more careful.

Conclusion

Despite the usefulness of all tissue sealants including BioGlue® in cardiovascular surgery, serious complications secondary to them are highlighted in the literature. The formation of a sterile abscess remains a rare complication but have a serious repercussion on a patient with the necessity of surgical revision. In this context, we recommend to limit the use of BioGlue® only to indicated cases with a word of caution.

Declaration of conflicting interests


The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Nurcan Yilmaz  <https://orcid.org/0000-0002-6543-0947>

Christoph Huber  <https://orcid.org/0000-0001-9048-849X>

References

1. Passage J, Jalali H, Tam RK, et al. BioGlue surgical adhesive—an appraisal of its indications in cardiac surgery. *Ann Thorac Surg* 2002; 74: 432–437.
2. Bhamidipati CM, Coselli JS and LeMaire SA. BioGlue in 2011: what is its role in cardiac surgery? *J Extra Corpor Technol* 2012; 44: 6–12.
3. Singh A, Wyatt M, Clarke M, et al. Late sterile abscess formation in carotid endarterectomy following use of BioGlue: a word of caution. *EJVES Short Rep* 2017; 37: 12–13.
4. Erasmi AW, Sievers HH and Wolschlag C. Inflammatory response after BioGlue application. *Ann Thorac Surg* 2002; 73: 1025–1026.
5. Pasic M, Unbehaun A, Drews T, et al. Late wound healing problems after use of BioGlue for apical hemostasis during transapical aortic valve implantation. *Interact Cardiovasc Thorac Surg* 2011; 13: 532–534.